Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Califf R. M., Harrelson-Woodlief L., Topol E. J. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation. 1990 Nov;82(5):1847–1853. doi: 10.1161/01.cir.82.5.1847. [DOI] [PubMed] [Google Scholar]
- Califf R. M., Topol E. J., Stack R. S., Ellis S. G., George B. S., Kereiakes D. J., Samaha J. K., Worley S. J., Anderson J. L., Harrelson-Woodlief L. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. Circulation. 1991 May;83(5):1543–1556. doi: 10.1161/01.cir.83.5.1543. [DOI] [PubMed] [Google Scholar]
- Corey L., Whitley R. J., Stone E. F., Mohan K. Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. Lancet. 1988 Jan 2;1(8575-6):1–4. doi: 10.1016/s0140-6736(88)90997-x. [DOI] [PubMed] [Google Scholar]
- De Vita C., Franzosi M. G., Geraci E., Maggioni A. P., Mauri F., Mezzanotte G., Tavazzi L., Tognoni G., Volpi A. GISSI-2: mortality plus extensive left-ventricular damage as "end-point". Lancet. 1990 Feb 3;335(8684):289–289. doi: 10.1016/0140-6736(90)90104-d. [DOI] [PubMed] [Google Scholar]
- Honan M. B., Harrell F. E., Jr, Reimer K. A., Califf R. M., Mark D. B., Pryor D. B., Hlatky M. A. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 1990 Aug;16(2):359–367. doi: 10.1016/0735-1097(90)90586-e. [DOI] [PubMed] [Google Scholar]
- Simoons M. L., Arnold A. E., Betriu A., de Bono D. P., Col J., Dougherty F. C., von Essen R., Lambertz H., Lubsen J., Meier B. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988 Jan 30;1(8579):197–203. doi: 10.1016/s0140-6736(88)91062-8. [DOI] [PubMed] [Google Scholar]
- Topol E. J., Califf R. M., George B. S., Kereiakes D. J., Abbottsmith C. W., Candela R. J., Lee K. L., Pitt B., Stack R. S., O'Neill W. W. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987 Sep 3;317(10):581–588. doi: 10.1056/NEJM198709033171001. [DOI] [PubMed] [Google Scholar]
- Topol E. J., Califf R. M., George B. S., Kereiakes D. J., Rothbaum D., Candela R. J., Abbotsmith C. W., Pinkerton C. A., Stump D. C., Collen D. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation. 1988 May;77(5):1100–1107. doi: 10.1161/01.cir.77.5.1100. [DOI] [PubMed] [Google Scholar]
- Topol E. J. Coronary angioplasty for acute myocardial infarction. Ann Intern Med. 1988 Dec 15;109(12):970–980. doi: 10.7326/0003-4819-109-12-970. [DOI] [PubMed] [Google Scholar]
- Verstraete M., Bernard R., Bory M., Brower R. W., Collen D., de Bono D. P., Erbel R., Huhmann W., Lennane R. J., Lubsen J. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985 Apr 13;1(8433):842–847. doi: 10.1016/s0140-6736(85)92208-1. [DOI] [PubMed] [Google Scholar]